BlossomHill Therapeutics, Inc.

Ce que BlossomHill Therapeutics, Inc. a publié le 18 septembre 2026

D’après le 8-K de l’entreprise.

Conférences de résultats

BlossomHill Therapeutics, Inc. n’a aucune transcription de conférence de résultats disponible.

Ce qu’a dit la direction

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter,”

Cité mot pour mot du communiqué, et affiché uniquement lorsque le document l’attribue à une personne nommée.

Comment le cours a réagi

Les communiqués tombent après la clôture ou avant l’ouverture, le mouvement est donc celui de la séance qui suit.

Ce que fait BlossomHill Therapeutics, Inc.

BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR ™ inhibitor for the treatment of EGFR -mutant NSCLC. BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies, BH-30643 demonstrated potent inhibitory activity across diverse EGFR mutation categories – classical mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions – while maintaining marked selectivity over wild-type EGFR. BH-30643 has received Fast Track designation and is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial spanning more than 40 sites in 10 countries. Ongoing dose expansion cohorts are enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov ( NCT06706076 ).

La description que l’entreprise donne d’elle-même, telle qu’elle figure au bas du communiqué.